Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

Autor: Moreno, V., Sepulveda, J.M., Vieito, M., Hernández-Guerrero, T., Doger, B., Saavedra, O., Ferrero, O., Sarmiento, R., Arias, M., De Alvaro, J., Di Martino, J., Zuraek, M., Sanchez-Pérez, T., Aronchik, I., Filvaroff, E.H., Lamba, M., Hanna, B., Nikolova, Z., Braña, I.

Publikováno v: In Annals of Oncology June 2020 31(6):780-788

Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC)

Autor: Paz-Ares, L, Juan-Vidal, O, Carcereny, E, Greillier, L, Navarro, A, Bennouna, J, Santoro, A, Berardi, R, Besse, B, Salvagni, S, Gonzalez, H, de Alvaro, J, Parra-Palau, J, Sanchez-Perez, T, Aronchik, I, Filvaroff, E, Lamba, M, Nikolova, Z, Ponce, S

Publikováno v: Annals of Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::b494a824c44977f1af58408adc61a101
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4128

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

8MO CC-90010, a reversible, potent oral bromodomain and extraterminal inhibitor (BETi) in patients (pts) with advanced solid tumours (aSTs) and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Longer follow-up from parts A & B and first reporting of part C of a phase I study

Autor: Moreno, V., Vieito Villar, M., Sepulveda Sanchez, J.M., Galvao, V., Hernández Guerrero, T., Doger, B., Saavedra, O., Carlo Stella, C., Michot, J-M., Italiano, A., Magagnoli, M., Carpio, C., Sarmiento, R., Amoroso, B., Aronchik, I., Filvaroff, E., Hanna, B., Pinto, A., Nikolova, Z., Braña, I.

Publikováno v: In Annals of Oncology March 2021 32 Supplement 1:S5-S5

559P Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC)

Autor: Paz-Ares, L., Juan-Vidal, O., Carcereny, E., Greillier, L., Navarro, A., Bennouna, J., Santoro, A., Berardi, R., Besse, B., Salvagni, S., Gonzalez, H., de Alvaro, J., Parra-Palau, J., Sánchez-Pérez, T., Aronchik, I., Filvaroff, E., Lamba, M., Nikolova, Z., Ponce, S.

Publikováno v: In Annals of Oncology September 2020 31 Supplement 4:S482-S483